Kyverna Therapeutics, Inc. (KYTX)
5.15
-0.01
(-0.19%)
USD |
NASDAQ |
Nov 04, 16:00
5.12
-0.03
(-0.58%)
After-Hours: 20:00
Kyverna Therapeutics Total Assets (Quarterly) : 219.82M for June 30, 2026
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 219.82M |
| March 31, 2026 | 257.02M |
| December 31, 2025 | 294.95M |
| September 30, 2025 | 187.16M |
| June 30, 2025 | 226.51M |
| March 31, 2025 | 260.66M |
| December 31, 2024 | 306.52M |
| September 30, 2024 | 339.20M |
| Date | Value |
|---|---|
| June 30, 2024 | 363.12M |
| March 31, 2024 | 389.98M |
| December 31, 2023 | 75.20M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 66.92M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
| Sangamo Therapeutics, Inc. | 59.96M |
| Sarepta Therapeutics, Inc. | 3.189B |
| Anixa Biosciences, Inc. | 15.07M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 54.27M |
| Shareholders Equity (Quarterly) | 165.55M |
| Debt to Equity Ratio | 0.1993 |
| Current Ratio | 9.058 |
| Net Debt Paydown Yield | -0.95% |